SARCLISA (Sanofi-Aventis Australia Pty Ltd)
Product name
SARCLISA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
187 (255 working days)
Active ingredients
isatuximab
Registration type
EOI
Indication
SARCLISA (concentrated injection) is now also indicated in combination with carfilzomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.